Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk.

The rate of completed suicides continues to rise across nations, cultures, socioeconomic classes, age groups, sexes, military personnel, veterans, and civilians from different backgrounds. Most concerning is the absence of diagnosed mental health disorders in the majority of these cases, per current literature reports. Efforts in the identification and possible prevention of this ultimate, tragic act of self-destruction have been minimally successful. In this article, the authors discuss the possible biological mechanisms including the role for potential markers, single nucleotide polymorphisms (SNPs), and their association with suicidal behaviors.

[1]  M. Ingelman-Sundberg,et al.  Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. , 2014, Pharmacogenomics.

[2]  I. Jaussent,et al.  A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances , 2014, The Pharmacogenomics Journal.

[3]  M. Ingelman-Sundberg,et al.  Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins , 2013, Clinical Cancer Research.

[4]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[5]  R. Viviani,et al.  CYP2D6 in the Brain: Impact on Suicidality , 2011, Clinical pharmacology and therapeutics.

[6]  N. Pedersen,et al.  Association between CYP2C19 polymorphism and depressive symptoms , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  A. Zackrisson,et al.  High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases , 2010, Clinical pharmacology and therapeutics.

[8]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[9]  A. Llerena,et al.  Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. , 2008, Pharmacogenomics.

[10]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[11]  A. Clayton,et al.  Blood brain barrier: the role of pyridoxine. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[12]  Ai-Ming Yu,et al.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.

[13]  B. Pomeranz,et al.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. , 1998, JAMA.

[14]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[15]  B Johansson,et al.  Substantial genetic influence on cognitive abilities in twins 80 or more years old. , 1997, Science.

[16]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[17]  R. Maynard,et al.  The Pharmacological Basis of Therapeutics. 9th ed , 1997 .

[18]  Swapan Mallick,et al.  The genomic landscape of Neanderthal ancestry in present-day humans. , 2016 .

[19]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[20]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .